PURPOSE: Polystyrene sulfonate (PSS) is a novel noncytotoxic antimicrobial contraceptive agent. A gel formulation of PSS was found safe for vaginal administration in phase I clinical trials. The purpose of the current study was to develop and evaluate novel bioadhesive vaginal film formulations of PSS. METHODS: PSS films were prepared by solvent evaporation and optimized for various physical, mechanical, and aesthetic properties. Further, films were evaluated for various biological activities and safety. RESULTS: Vaginal films containing 300 mg PSS per unit have been developed, using generally regarded as safe (GRAS) listed excipients. The films are colorless, transparent, thin, soft, and tough, dissolve rapidly in physiologic fluid to form a smooth, viscous and bioadhesive solution that could be retained in the vagina for prolonged intervals. Sperm function inhibition (hyaluronidase and cervical mucus penetration) and antimicrobial activities against human immunodeficiency virus (HIV) and herpes simplex virus (HSV) by PSS films were found comparable to PSS. Also, films did not inhibit normal vaginal microflora (Lactobacillus) and were noncytotoxic as indicated by negligible sperm immobilization and cytotoxicity to host cell assays. CONCLUSIONS: Rapidly dissolving bioadhesive vaginal film formulation of PSS with desired physical, mechanical, aesthetic, and biological properties is a suitable candidate vaginal microbicide for prevention of sexually transmitted disease (STDs) and is ready for toxicological and clinical evaluation.
PURPOSE:Polystyrene sulfonate (PSS) is a novel noncytotoxic antimicrobial contraceptive agent. A gel formulation of PSS was found safe for vaginal administration in phase I clinical trials. The purpose of the current study was to develop and evaluate novel bioadhesive vaginal film formulations of PSS. METHODS:PSS films were prepared by solvent evaporation and optimized for various physical, mechanical, and aesthetic properties. Further, films were evaluated for various biological activities and safety. RESULTS: Vaginal films containing 300 mg PSS per unit have been developed, using generally regarded as safe (GRAS) listed excipients. The films are colorless, transparent, thin, soft, and tough, dissolve rapidly in physiologic fluid to form a smooth, viscous and bioadhesive solution that could be retained in the vagina for prolonged intervals. Sperm function inhibition (hyaluronidase and cervical mucus penetration) and antimicrobial activities against human immunodeficiency virus (HIV) and herpes simplex virus (HSV) by PSS films were found comparable to PSS. Also, films did not inhibit normal vaginal microflora (Lactobacillus) and were noncytotoxic as indicated by negligible sperm immobilization and cytotoxicity to host cell assays. CONCLUSIONS: Rapidly dissolving bioadhesive vaginal film formulation of PSS with desired physical, mechanical, aesthetic, and biological properties is a suitable candidate vaginal microbicide for prevention of sexually transmitted disease (STDs) and is ready for toxicological and clinical evaluation.
Authors: Sanjay Garg; Kaustubh R Tambwekar; Kavita Vermani; Raghupathi Kandarapu; Alka Garg; Donald P Waller; Lourens J D Zaneveld Journal: AIDS Patient Care STDS Date: 2003-08 Impact factor: 5.078
Authors: C Coggins; C J Elias; R Atisook; M T Bassett; V Ettiègnene-Traoré; P D Ghys; L Jenkins-Woelk; E Thongkrajai; N L VanDevanter Journal: AIDS Date: 1998-07-30 Impact factor: 4.177
Authors: Lourens J D Zaneveld; Donald P Waller; Robert A Anderson; Calvin Chany; William F Rencher; Kenneth Feathergill; Xiao-Hui Diao; Gustavo F Doncel; Betsy Herold; Morris Cooper Journal: Biol Reprod Date: 2002-04 Impact factor: 4.285
Authors: B C Herold; N Bourne; D Marcellino; R Kirkpatrick; D M Strauss; L J Zaneveld; D P Waller; R A Anderson; C J Chany; B J Barham; L R Stanberry; M D Cooper Journal: J Infect Dis Date: 2000-02 Impact factor: 5.226
Authors: R A Anderson; K Feathergill; R Kirkpatrick; L J Zaneveld; K T Coleman; P G Spear; M D Cooper; D P Waller; J G Thoene Journal: J Androl Date: 1998 Jan-Feb
Authors: A B Sassi; M R Cost; A L Cole; A M Cole; D L Patton; P Gupta; L C Rohan Journal: Antimicrob Agents Chemother Date: 2011-02-14 Impact factor: 5.191
Authors: Michael C Koetting; Jonathan T Peters; Stephanie D Steichen; Nicholas A Peppas Journal: Mater Sci Eng R Rep Date: 2015-05-16 Impact factor: 36.214
Authors: Anthony S Ham; Lisa Cencia Rohan; Ashlee Boczar; Lu Yang; Karen W Buckheit; Robert W Buckheit Journal: Pharm Res Date: 2012-03-06 Impact factor: 4.200
Authors: Ayman Akil; Michael A Parniak; Charlene S Dezzuitti; Bernard J Moncla; Marilyn R Cost; Mingguang Li; Lisa Cencia Rohan Journal: Drug Deliv Transl Res Date: 2011-06-01 Impact factor: 4.617